Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Neurocrine Bioscienc
(NQ:
NBIX
)
145.01
-2.76 (-1.87%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Neurocrine Bioscienc
< Previous
1
2
3
4
5
6
7
8
Next >
Looking Into Neurocrine Biosciences's Return On Capital Employed
February 14, 2022
Benzinga Pro data, Neurocrine Biosciences (NASDAQ:NBIX) reported Q4 sales of $312.00 million. Earnings fell to a loss of $7.30 million, resulting in a 132.44% decrease from last quarter.
Via
Benzinga
Why Neurocrine Biosciences Are Trading Higher Today?
February 11, 2022
Neurocrine Biosciences Inc (NASDAQ: NBIX) reported Q4 Ingrezza sales of $301 million, +25% Y/Y, with total prescriptions up 32% Overall sales increased $312.0 million...
Via
Benzinga
The Daily Biotech Pulse: Adcom Recommends Additional Trials For Lilly's Partnered Cancer Drug, Novavax Touts Pediatric Vaccine Data, TC Biopharm IPO
February 11, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adcom Rules That Lilly May Have To Conduct Additional Studies For Co-...
Via
Benzinga
Recap: Neurocrine Biosciences Q4 Earnings
February 11, 2022
Neurocrine Biosciences (NASDAQ:NBIX) reported its Q4 earnings results on Friday, February 11, 2022 at 07:30 AM. Here's what investors need to know about the announcement. Earnings Neurocrine...
Via
Benzinga
Earnings Scheduled For February 11, 2022
February 11, 2022
Companies Reporting Before The Bell • Mr. Cooper Group (NASDAQ:COOP) is expected to report quarterly earnings at $1.22 per share on revenue of $551.60 million.
Via
Benzinga
Analyst Ratings For Neurocrine Biosciences
February 01, 2022
Within the last quarter, Neurocrine Biosciences (NASDAQ:NBIX) has observed the following analyst ratings:
Via
Benzinga
A Preview Of Neurocrine Biosciences's Earnings
February 10, 2022
Neurocrine Biosciences (NASDAQ:NBIX) is set to give its latest quarterly earnings report on Friday, 2022-02-11. Here's what investors need to know before the announcement. Analysts estimate that...
Via
Benzinga
The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, IPOs And More
February 06, 2022
Biotech stocks managed to close the week ending Feb. 4 with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid negative reaction to some big...
Via
Benzinga
10 Biggest Price Target Changes For Tuesday
January 18, 2022
Keybanc raised J.B. Hunt Transport Services, Inc. (NASDAQ:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 18, 2022
January 18, 2022
Upgrades Canaccord Genuity upgraded the previous rating for Fortuna Silver Mines Inc (NYSE:
Via
Benzinga
Xenon Receives $15M Regulatory Milestone Under Epilepsy Pact With Neurocrine
January 12, 2022
Xenon Pharmaceuticals Inc's (NASDAQ: XENE) collaboration to develop treatments for epilepsy with Neurocrine Biosciences Inc (NASDAQ: NBIX) achieved a regulatory...
Via
Benzinga
Analyst Ratings For Neurocrine Biosciences
January 07, 2022
Over the past 3 months, 9 analysts have published their opinion on Neurocrine Biosciences (NASDAQ:
Via
Benzinga
The Daily Biotech Pulse: Glaukos Gets FDA Nod, Neurocrine Preannounces Soft Ingrezza Sales, 3 IPOs
January 07, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Hepion's Lead NASH Drug Candidate Gets The Non-Proprietary Name...
Via
Benzinga
Expert Ratings For Neurocrine Biosciences
December 08, 2021
Neurocrine Biosciences (NASDAQ:NBIX) has observed the following analyst rat...
Via
Benzinga
The Daily Biotech Pulse: Valneva Strikes Deal To Supply COVID Vaccine to Bahrain, TherapeuticsMD & Amneal Settle Patent Lawsuit, Reata Awaits Adcom
December 08, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus EyePoint Announces Commercialization Agreement For Dexycu To Treat Post-...
Via
Benzinga
Topics
Intellectual Property
Lawsuit
Exposures
Financial
Intellectual Property
Legal
Neurocrine's Ingrezza Meets Primary Goal In Phase 3 Study In Patients With Involuntary Muscle Movement
December 08, 2021
Neurocrine Biosciences Inc (NASDAQ: NBIX) revealed topline data from its Phase 3 KINECT-HD study evaluating Ingrezza (valbenazine) for chorea associated with...
Via
Benzinga
Neurocrine Pens $2.6B Pact With Sosei Heptares For Neuro Targets
November 22, 2021
Neurocrine Biosciences Inc (NASDAQ: NBIX) has outlined a deal that provides Sosei Heptares Corporation $100 million upfront, R&D expenses, and a...
Via
Benzinga
Mobile Mental Health: Coming to a Home Near You?
November 18, 2021
Photo by Anna Shvets from Pexels The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial...
Via
Benzinga
Analyst Ratings For Neurocrine Biosciences
November 17, 2021
Neurocrine Biosciences (NASDAQ:NBIX) has observed the following analyst rat...
Via
Benzinga
Why Neurocrine Biosciences Shares Fell Nearly 10% Today
November 02, 2021
Investors have grown weary of unpredictable profitability and unexpected expenses.
Via
The Motley Fool
12 Health Care Stocks Moving In Tuesday's Intraday Session
November 02, 2021
Gainers Kiniksa Pharmaceuticals (NASDAQ:KNSA) stock increased by 16.73% to $14.86 during Tuesday's regular session. The current volume of 1.0 million shares is 269.7%...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021
November 19, 2021
Upgrades Morgan Stanley upgraded the previous rating for EQT Corp (NYSE:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 17, 2021
November 17, 2021
Upgrades According to Williams Capital, the prior rating for On Holding AG (NYSE:
Via
Benzinga
What 5 Analyst Ratings Have To Say About Neurocrine Biosciences
November 02, 2021
Over the past 3 months, 5 analysts have published their opinion on Neurocrine Biosciences (NASDAQ:
Via
Benzinga
71 Biggest Movers From Yesterday
November 03, 2021
Gainers Avis Budget Group, Inc. (NASDAQ: CAR) shares climbed 108.3% to close at $357.17 on Tuesday after the company reported better-than-expected Q3 adjusted EPS and sales...
Via
Benzinga
The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US
November 02, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus SAB Spikes On Analyst Action SAB Biotherapeutics, Inc. (NASDAQ: SABS) shares...
Via
Benzinga
Exposures
COVID-19
Neurocrine Biosciences, Inc (NBIX) Q3 2021 Earnings Call Transcript
November 01, 2021
NBIX earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
12 Health Care Stocks Moving In Monday's After-Market Session
November 01, 2021
Gainers Biophytis (NASDAQ:BPTS) shares mo...
Via
Benzinga
Neurocrine Biosciences: Q3 Earnings Insights
November 01, 2021
Neurocrine Biosciences (NASDAQ:NBIX) reported its Q3 earnings results on Monday, November 1, 2021 at 04:01 PM. Here's what investors need to know about the announcement....
Via
Benzinga
Neurocrine Biosciences's Return On Capital Employed Overview
November 01, 2021
According to Benzinga Pro, during Q2, Neurocrine Biosciences (NASDAQ:NBIX) earned $62.80 million, a 99.37% increase from the preceding quarter. Neurocrine Biosciences also posted...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.